Biomarin Pharmaceutical Inc. (BMRN)
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.
5 Undervalued Price-to-Book Stocks Worth Buying in August
BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
BMRN vs. ILMN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth
BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller.
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical Q2 Earnings Call Highlights
BioMarin Pharmaceutical NASDAQ: BMRN reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed Amicus acquisition supported results. The company raised its full-year revenue, VOXZOGO revenue and non-GAAP diluted earnings-per-share guidance, though it did not provide updated ranges during the call.
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.2 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.44 per share a year ago.
